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BACKGROUND: Although left ventricular noncompaction (LVNC) has 
been associated with an increased risk of adverse cardiovascular events, 
the accurate incidence of cardiovascular morbidity and mortality is 
unknown. We, therefore, aimed to assess the incidence rate of LVNC-
related cardiovascular events.
METHODS: We systematically searched observational studies reporting 
the adverse outcomes related to LVNC. The primary end point was 
cardiovascular mortality.
RESULTS: We identiﬁed 28 eligible studies enrolling 2501 LVNC patients 
(mean age, 46 years; male/female ratio, 1.7). After a median follow-up 
of 2.9 years, the pooled event rate for cardiovascular mortality was 1.92 
(95% CI, 1.54–2.30) per 100 person-years. LVNC patients had a similar 
risk of cardiovascular mortality compared with a dilated cardiomyopathy 
control group (odds ratio, 1.10 [95% CI, 0.18–6.67]). The incidence rates 
of all-cause mortality, stroke and systemic emboli, heart failure admission, 
cardiac transplantation, ventricular arrhythmias, and cardiac device 
implantation were 2.16, 1.54, 3.53, 1.24, 2.17, and 2.66, respectively, 
per 100 person-years. Meta-regression and subgroup analyses revealed 
that left ventricular ejection fraction, not the extent of left ventricular 
trabeculation, had an important inﬂuence on the variability of incidence 
rates. The risks of thromboembolism and ventricular arrhythmias in LVNC 
patients were similar to dilated cardiomyopathy patients. However, LVNC 
patients had a higher incidence of heart failure hospitalization than 
dilated cardiomyopathy patients.
CONCLUSIONS: Patients with LVNC carry a similar cardiovascular risk 
when compared with dilated cardiomyopathy patients. Left ventricular 
ejection fraction—a conventional indicator of heart failure severity, not 
the extent of trabeculation—appears to be an important determinant of 
adverse outcomes in LVNC patients.
REGISTRATION: https://www.crd.york.ac.uk/PROSPERO/ Unique 
identiﬁer: CRD42018096313.
© 2020 The Authors. Circulation: 
Cardiovascular Imaging is published 
on behalf of the American Heart 
Association, Inc., by Wolters Kluwer 
Health, Inc. This is an open access 
article under the terms of the Creative 
Commons Attribution License, 
which permits use, distribution, and 
reproduction in any medium, provided 
that the original work is properly cited.
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L
eft ventricular noncompaction (LVNC) cardiomyop-
athy is characterized by prominent left ventricular 
(LV) trabeculations, deep intertrabecular recesses 
communicating with the ventricular cavity, and a thin 
and compacted epicardial layer. While LVNC is consid-
ered a genetic cardiomyopathy by the American Heart 
Association,1 the European Society of Cardiology cat-
egorizes it as an unclassiﬁed cardiomyopathy.2 Multi-
ple pathogeneses of the LVNC phenotype have been 
proposed: it may be familial (inherited) or nonfamilial 
(sporadic and proven absent in relatives) and may occur 
as an isolated disease or in association with genetic dis-
eases and congenital defects.3 Nonfamilial and sporadic 
forms have been described in highly trained athletes,4 
sickle cell anemia,5 and pregnancy.6 The genetic basis of 
familial LVNC is still controversial. Most familial cases of 
LVNC are associated with mutations in the same genes 
associated with other types of inherited cardiomyopa-
thies (Figure 1A).7
The diagnosis of LVNC has conventionally been made 
by imaging the LV and demonstrating the presence of 
speciﬁc criteria based mostly upon the relative thickness 
of the compacted myocardial wall and the mesh of tra-
beculated (noncompacted) layer of cardiac muscle using 
either echocardiography or cardiovascular magnetic res-
onance imaging (Figure 1B). All current methodologies 
used to establish a diagnosis have strengths and weak-
nesses in how they are derived, their ease of use, the 
time to acquire the relevant images, and their diagnostic 
accuracy, but there is no evidence to suggest that any 
particular criteria or imaging modality is superior. How-
ever, as image quality and awareness of diagnostic crite-
ria have improved, the LVNC phenotype has emerged as 
an increasingly recognized ﬁnding with the inherent risk 
of overdiagnosis noted as a signiﬁcant concern.8
The clinical outcomes of LVNC vary widely in the 
reported literature, which perhaps reﬂects the under-
lying diversity of study cohorts. In view of the contin-
ued uncertainty, we conducted a systematic review of 
observational cohort studies to explore the clinical out-
comes of patients considered to be affected by LVNC.
METHODS
The data, analytic methods, and study materials can be 
obtained from the corresponding author for purposes of 
reproducing the results or replicating the results. Because this 
is a meta-analysis of aggregate data from the published lit-
erature, no informed consent was required. Likewise, because 
we have not recruited new patients, an institutional review 
board’s approval was not necessary.
We aimed to explore the adverse outcomes of patients 
with LVNC through a systematic review of the litera-
ture including prospective longitudinal and retrospective 
observational studies. The complete study protocol was 
registered on PROSPERO—an international database of 
CLINICAL PERSPECTIVE
In this large meta-analysis of adult patients with 
left ventricular noncompaction identiﬁed by cur-
rently accepted imaging criteria, the incidences of 
objective cardiovascular outcomes appear compa-
rable to those observed in dilated cardiomyopa-
thy. The frequency of adverse outcomes is mostly 
driven by left ventricular systolic impairment rather 
than the burden of trabeculation. The diversity of 
current imaging diagnostic criteria for left ventric-
ular noncompaction creates signiﬁcant challenges 
for accurate phenotyping. Further prospective clin-
ical registries with access to individual-level data 
are required to standardize the left ventricular non-
compaction diagnostic criteria, comorbidities, and 
outcome measures to fully evaluate the prognostic 
markers of this poorly understood condition.
Figure 1. Genotype and phenotype of LVNC. 
A, Venn diagram of the number of genes associated with inherited cardio-
myopathy; (B) cardiovascular magnetic resonance images demonstrating a 
classic left ventricular noncompaction (LVNC) with a 2-layer appearance of 
thin compact myocardium and excessive trabeculation (top left), isolated LVNC 
with normal chamber size and function (top right), mixed dilated cardiomy-
opathy (DCM) and LVNC with biventricular involvement (bottom left), and 
hypertrophic cardiomyopathy (HCM) with features of LVNC (bottom right). 
ARVC indicates arrhythmogenic right ventricular cardiomyopathy.
?????????????????????????????????????????????????????????????
Circ Cardiovasc Imaging. 2020;13:e009712. DOI: 10.1161/CIRCIMAGING.119.009712 January 2020 3
Aung et al; Meta-Analysis of Prognosis in LVNC
prospectively registered systematic reviews—and can be 
accessed at www.crd.york.ac.uk/PROSPERO/display_record.
php?ID=CRD42018096313.
We recognized the challenges associated with meta-analy-
ses of observational studies because of variable study designs 
and inherent biases. Therefore, we conducted this systematic 
review following the recommendations by the Meta-Analysis 
of Observational Studies in Epidemiology group9 and the 
PRISMA (Preferred Reporting Items for Systematic Reviews 
and Meta-Analyses) guidelines.10
Search Strategy
We searched PubMed and Embase databases, the Cochrane 
Database of Systematic Reviews, the PROSPERO database 
(www.crd.york.ac.uk/prospero), and the Clinical Trials Registry 
(www.clinicaltrials.gov), as well as abstracts from major cardi-
ological societies for potentially relevant articles using a com-
bination of key words related to trabeculation or LVNC and the 
cardiovascular outcomes for the period from January 1, 1966, 
to July 3, 2019, without any language restriction. Details of 
the search terms are provided in the Data Supplement.
Selection Criteria
Inclusion criteria were (1) patients >18 years old; (2) a diagno-
sis of LVNC by echocardiographic or cardiovascular magnetic 
resonance criteria; (3) crude or adjusted event rates of all-
cause mortality, cardiovascular mortality, ventricular arrhyth-
mias, sudden cardiac death, heart failure hospitalization, 
myocardial infarction, stroke, systemic embolic events, new 
cardiac implantable electronic device, and heart transplanta-
tion. Deﬁnitions of excessive trabeculation according to car-
diac imaging were deﬁned by Petersen et al,11 Chin et al,12 
Jenni et al,13 Jacquier et al,14 Grothoff et al,15 Stacey et al,16 
Stöllberger et al,17 or Captur et al18 criteria. We excluded case 
reports, nonoutcome studies, and reviews.
Data Extraction
Two authors (F.R., S.D.) performed the screening of titles and 
abstracts, reviewed the full-text articles, and determined their 
eligibility. Divergences were solved by consensus or involving 
the third author (N.A.). We also handsearched the reference 
list of all eligible articles for additional relevant studies.
We collated study-level covariates and events reported 
in original publications, using a standardized data extraction 
form. We translated relevant non-English articles into English. 
We contacted the authors of studies where clariﬁcation of 
data was required. In studies with overlapping cohorts, we 
used the data from the most recent study or the study with 
the largest sample size.
Quality Assessment
We assessed the individual study-level quality by the Quality 
in Prognosis Studies tool,19 which evaluates 32 key consider-
ations across 6 bias domains: (1) study participation, (2) study 
attrition, (3) prognostic factor measurement, (4) outcome 
measurement, (5) study confounding, and (6) statistical analy-
sis and reporting. An overall quality grade (high quality, inter-
mediate quality, and low quality) was assigned to each study 
after considering all 6 bias domains. Two authors (M.Y.K. and 
A.A.-B.) independently rated the quality items, and disagree-
ments were resolved by another author (N.A.).
Outcomes
The primary end point was the incidence of cardiovascular 
mortality. Secondary end points included incidences of all-
cause mortality, stroke and systemic embolic events, heart 
failure requiring hospitalization, cardiac transplantation, ven-
tricular arrhythmias (ventricular tachycardia or ventricular ﬁbril-
lation), and cardiac device implantation deﬁned as insertion of 
implantable cardioverter deﬁbrillator or cardiac synchronization 
therapy with implantable cardioverter deﬁbrillator.
Statistical Analysis
Dichotomous variables were reported as percentages, with 
continuous variables reported as mean±SD or median (inter-
quartile range [IQR]), based on data distribution. For each 
included study, we calculated an event rate with its 95% CI 
for every predeﬁned outcome. Event rates were computed as 
the ratio between the number of events and the person-time 
in years at risk, to account for the heterogeneity of follow-
up duration across different studies. We performed Freeman-
Tukey transformation20 of the number of events for variance 
stabilization. We added 0.5 to the count in studies with zero 
event to achieve numerical stability. For studies reporting the 
event rates in both LVNC subjects and non-LVNC controls, we 
calculated odds ratio and 95% CI for each outcome.
We used random-effects models to estimate the summary 
pooled event rates or odd ratios of prespeciﬁed outcomes 
using the DerSimonian and Laird method. We graphically pre-
sented the results in forest plots, with point estimates of the 
effect size and 95% CI for each study and the combined esti-
mate. The area of squares and diamonds in the forest plots 
are proportional to each study weight.
We assessed funnel plot asymmetry, which could result 
from publication bias. We additionally used the Egger regres-
sion asymmetry test for end points with asymmetrical funnel 
plots. We also performed the nonparametric trim-and-ﬁll pro-
cedure, which adjusts for funnel plot asymmetry by computing 
hypothetical missing studies. We formally assessed statistical 
heterogeneity by a χ2 test and quantiﬁed it using the inconsis-
tency index (I2) statistic, which ranges from 0% to 100% and 
is deﬁned as the percentage of observed between-trial vari-
ability that is due to heterogeneity rather than chance. A lack 
of homogeneity was considered to be signiﬁcant with an I2 
≥50%. We anticipated a high degree of heterogeneity across 
individual studies because of the multiplicity of LVNC diagnos-
tic criteria and the variability of inclusion and exclusion criteria 
used by individual studies. Accordingly, we used random-
effects models to account for the between-study variabilities 
in the effect estimates. To explore the possible reasons of het-
erogeneity, we performed the following secondary analyses: 
(1) univariate meta-regression assessing the mediating effect 
of age, sex (percentage of men), New York Heart Association 
(NYHA) classiﬁcation, LV end-diastolic diameter, and LVNC/LV 
compaction ratio (for thromboembolic end point, we addi-
tionally investigated the mediating effects of the percentage 
of prevalent atrial ﬁbrillation); (2) subgroup analyses accord-
ing to person-time at risk in years (sample size multiplied by 
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mean follow-up years), presence of moderate-to-severe LV 
systolic dysfunction (by LV ejection fraction [LVEF] <45%) at 
the time of recruitment, and overall quality of included stud-
ies. We also sought to compare the event rates of the LVNC 
patients in our study with a recently published meta-analysis 
of nonischemic dilated cardiomyopathy (DCM) patients,21 
which reported the incidences of cardiovascular mortality, 
heart failure hospitalization, and ventricular arrhythmias. We 
extracted the sample size, absolute number of events, and 
follow-up duration of individual studies from this DCM meta-
analysis to calculate the incidence rate per 100 person-years. 
The difference in effect estimates between the disease groups 
and subgroups was assessed with Z test. We evaluated the 
impact of a single study on the overall pooled estimate in 
meta-analysis by removing one study at a time and recomput-
ing the pooled result; this procedure is known as leave-one-
out analysis. Additional details on the statistical tests were 
outlined in the Data Supplement.
A 2-sided P<0.05 was considered statistically signiﬁcant. 
We performed all analyses and constructed graphs using the 
metafor package22 in R, version (3.5.0).23
RESULTS
Our search strategy yielded 2879 studies, of which 94 
full texts were relevant for evaluation (Figure 2). Exclu-
sion of nonrelevant studies, review articles, and stud-
ies with duplicated cohorts resulted in 28 publications 
related to outcomes in LVNC. Searches of the Clinical 
Trials Registry identiﬁed one ongoing study titled “Prog-
nosis of Isolated Left Ventricular Non-Compaction in 
Adults” in France.
The ﬁnal list (28 studies) consisted of 13 prospective 
and 15 retrospective observational studies. The stud-
ies were published between 1997 and 2019. A total 
of 2501 patients were included (mean±SD age, 46±7 
years; male/female ratio, 1.7) with an overall median 
follow-up of 2.8 (IQR, 2.3–4.1) years. Although the 
diagnosis of LVNC was based mainly on quantiﬁcation 
of excessive trabeculation, the majority of included 
studies (18 of 28) comprised cohorts with signiﬁcantly 
impaired LV systolic function (mean LVEF, <45%). The 
main characteristics of included studies are presented in 
Table.24–51 Among 28 studies, the distribution of overall 
study quality was 18%, 50%, and 32% for high, inter-
mediate, and low quality, respectively (Figure 3).
Primary Outcome
Of 28 included studies, 22 studies provided data on car-
diovascular mortality in a total of 1822 patients who 
were followed up for a median (IQR) duration of 2.9 
(2.4–4.4) years. The pooled incidence rate of cardiovas-
cular death was 1.92 (95% CI, 1.54–2.30) per 100 per-
son-years (Figure 425–31,33–38,40–44,47–50). The funnel plot for 
the primary outcome appeared asymmetrical because of 
the absence studies in the lower left corner, raising the 
possibility of publication bias (Egger regression asym-
metry test, P=0.048). Addition of hypothetical missing 
studies (n=6) by the trim-and-ﬁll method reduced the 
pooled cardiovascular mortality rate to 1.64 (95% CI, 
1.29–1.98) per 100 person-years (Figure 5).
We observed a substantial between-study hetero-
geneity (I2=89.6%; P<0.0001). Therefore, we explored 
the clinical and statistical sources of heterogeneity by 
meta-regression and subgroup analyses. The meta-
regression analyses investigating the mediating effects 
of age, proportion of men, proportion of patients with 
NYHA >2, LV end-diastolic diameter, and LVNC/LV 
compaction ratio did not identify any signiﬁcant asso-
ciation. In subgroup analyses, studies enrolling patients 
with moderate-to-severe LV impairment (LVEF <45%) 
appeared to have a higher incidence of cardiovascu-
lar mortality, compared with studies including patients 
with mildly impaired or normal LV systolic function (LVEF 
≥45%; 2.21 [95% CI, 1.82–2.61] cardiovascular deaths 
per 100 person-years, I2=76.5%, versus 1.19 [95% CI, 
0.26–2.13] cardiovascular deaths per 100 person-years, 
I2=93.2%; P for subgroup difference, 0.048). There was 
Figure 2. Flowchart demonstrating the 
process of study selection.
?????????????????????????????????????????????????????????????
Circ Cardiovasc Imaging. 2020;13:e009712. DOI: 10.1161/CIRCIMAGING.119.009712 January 2020 5
Aung et al; Meta-Analysis of Prognosis in LVNC
Table. Characteristics of Included Studies
Author Year
Cohort 
Characteristics Control Group N Age, y
Male 
Sex, 
n
LVNC Imaging 
Diagnostic 
Criteria LVEF, %
LV End-
Diastolic 
Dimension*
Follow-Up 
Duration, 
mo End Points
Amzulescu24 2015 Prospective single-
center study of 
nonischemic DCM 
patients with 
coexisting LVNC
None 59 52±13 34 Petersen 24.1±8.3 69±9 mm 40.8 Thromboembolic 
event
Andreini25 2016 Prospective 
multicenter study 
of LVNC patients
None 113 44±17 70 Jenni+Petersen 42.8±16.2 79.7±26.3 
mL/m2
48±24 CV mortality, 
thromboembolic 
event, ventricular 
arrhythmia, heart 
failure
Aras26 2006 Retrospective 
single-center study 
of LVNC patients
None 67 41±18 44 Jenni 43.5±14.4 58±10 mm 30±12 All-cause mortality, 
CV mortality, 
thromboembolic 
event, ventricular 
arrhythmia, heart 
failure
Asfalou27 2016 Retrospective 
single-center study 
of LVNC patients
None 23 47±13 15 Jenni 27±8 67.7±6.6 
mm
24 All-cause mortality, 
CV mortality, 
thromboembolic 
event, ventricular 
arrhythmia, ICD 
implantation, heart 
failure
Caliskan28 2011 Prospective single-
center study of 
LVNC patients
None 77 40±14 37 Jenni NR 60.4±9.6 
mm
33±24 All-cause mortality, 
CV mortality, 
ventricular 
arrhythmia, cardiac 
transplantation, 
heart failure
Cetin29 2016 Retrospective 
single-center study 
of LVNC patients
None 88 39±18 57 Jenni 32.0±12.5 59.3±9.1 
mm
42.4 All-cause mortality, 
CV mortality, 
ventricular 
arrhythmia, ICD 
implantation
Correia30 2011 Retrospective 
single-center study 
of LVNC patients
None 20 53±20 13 Jenni 45±19 58±11 mm 12±6 All-cause mortality, 
CV mortality, cardiac 
transplantation, ICD 
implantation
Enriquez31 2011 Retrospective 
single-center study 
of LVNC patients
None 15 52±17 6 Jenni 27±10 66±11 mm 19 Ventricular 
arrhythmia, ICD 
implantation
Gaye32 2017 Retrospective 
multicenter study 
of LVNC patients
None 35 47±18 NR Jenni 32.5±13.8 66.4±9.6 
mm
17.2±14.5 All-cause mortality, 
ventricular 
arrhythmia, heart 
failure
Greutmann33 2012 Retrospective 
single-center study 
of LVNC patients
None 132 41±17 46 Jenni 41±18 34±7 mm/
m2
32.4 CV mortality, 
thromboembolic 
event, ventricular 
arrhythmia, cardiac 
transplantation, 
heart failure
Habib34 2011 Prospective 
multicenter study 
of LVNC patients
None 105 45±17 69 Jenni 46±18 63±11 mm 30±18 All-cause mortality, 
CV mortality, 
thromboembolic 
event, ventricular 
arrhythmia, ICD 
implantation, 
cardiac 
transplantation, 
heart failure
Ivanov35 2017 Prospective single-
center study of 
LVNC patients
Patients not 
fulﬁlling Petersen 
criteria and with 
no evidence of 
congenital heart 
disease or valve 
disease
276 
(LVNC)/424 
(non-
LVNC with 
comparable 
age and 
LVEF)
57 147 Petersen 49±17 77±29 mL/
m2
82 All-cause mortality, 
CV mortality
(Continued )
?????????????????????????????????????????????????????????????
Circ Cardiovasc Imaging. 2020;13:e009712. DOI: 10.1161/CIRCIMAGING.119.009712 January 2020 6
Aung et al; Meta-Analysis of Prognosis in LVNC
Kawasaki36 2005 Retrospective 
single-center study 
of LVNC patients
Age and sex 
matched with 
individuals with 
myocardial 
infarction, HCM, 
and no CV 
disease
10 (LVNC)/80 
(non-LVNC: 
40 MI and 
40 HCM)†
50±13 8 Jenni NR NR 26±14 All-cause mortality, 
CV mortality
Li37 2018 Prospective single-
center study of 
Chinese LVNC 
patients
None 83 45 58 Jenni+Petersen 37 62 54 All-cause mortality, 
CV mortality, cardiac 
transplantation
Loﬁego38 2007 Prospective 
multicenter study 
of LVNC patients
None 65 45±16 NR Jenni 31±11 67±11 mm 46±44 All-cause mortality, 
CV mortality, 
thromboembolic 
event, ventricular 
arrhythmia, ICD 
implantation, 
cardiac 
transplantation, 
heart failure
Mazurkiewicz39 2017 Prospective single-
center study of 
DCM patients with 
coexisting LVNC
DCM patients 
not fulﬁlling 
LVNC criteria
127 
(LVNC)/149 
(DCM)
33±9 78 Grothoff 27.7±7.5 172.9±29.8 
mL/m2
28.8 All-cause 
mortality, cardiac 
transplantation, 
thromboembolic 
event
Murphy40 2005 Prospective study 
of unrelated LVNC 
patients
None 45 37±17 28 Chin+Jenni NR 58±11 mm 46 All-cause mortality, 
CV mortality, 
ventricular 
arrhythmia, ICD 
implantation
Peters41 2014 Prospective single-
center study of 
idiopathic LVNC 
patients
None 55 42±12 21 Jenni 29.6±11.8 59.1±9.8 
mm
16.7±5.9 All-cause mortality, 
CV mortality, 
thromboembolic 
event, heart 
failure, ICD 
implantation
Ritters42 1997 Retrospective 
single-center study 
of LVNC patients
None 17 42±17 14 Jenni NR NR 30±28 All-cause mortality, 
CV mortality, 
thromboembolic 
event, cardiac 
transplantation, 
heart failure, 
ventricular 
arrhythmia
Salazar-
Mendiguchía43
2019 Retrospective 
multicenter study 
of LVNC patients
Symptomatic 
DCM patients
75 50±15 51 Jenni 32 63.8 60 CV mortality, 
thromboembolic 
event, cardiac 
transplantation, 
ventricular 
arrhythmia, ICD 
implantation
Sedaghat-
Hamedani44
2017 Prospective 
multicenter registry 
of symptomatic 
LVNC patients
Age-matched 
nonischemic 
DCM patients
68 
(LVNC)/247 
(DCM)
41±14 48 Jenni+
Stöllberger+
Petersen
38±15.3 62±12.3 
mm
61 All-cause mortality, 
CV mortality, 
thromboembolic 
event, cardiac 
transplantation, 
ventricular 
arrhythmia, ICD 
implantation
Stampﬂi45 2017 Retrospective 
multicenter study 
of LVNC patients
None 153 43±19 91 Jenni 45 NR 72 All-cause 
mortality, cardiac 
transplantation
Stanton46 2009 Retrospective 
single-center study 
of LVNC patients
Age-, sex-, and 
LVEF-matched 
DCM patients
30 (LVNC)/27 
(DCM)
39±20 18 Jenni 41 NR 30±14 All-cause mortality, 
ventricular 
arrhythmia, ICD 
implantation
Table. Continued
Author Year
Cohort 
Characteristics Control Group N Age, y
Male 
Sex, 
n
LVNC Imaging 
Diagnostic 
Criteria LVEF, %
LV End-
Diastolic 
Dimension*
Follow-Up 
Duration, 
mo End Points
(Continued )
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no signiﬁcant difference in event rates when stratiﬁed 
by person-time at risk (an amalgamation of sample size 
and follow-up duration) of >3 years and high/interme-
diate versus low-quality studies (Figure 6).
The overall estimate of cardiovascular mortality 
did not change signiﬁcantly in the leave-one-out sen-
sitivity analysis indicating that no single study had an 
overwhelming impact on the combined meta-analysis 
estimate (Figure I in the Data Supplement).
Secondary Outcomes
All-Cause Mortality
Twenty-four studies documented the incidence of 
all-cause mortality in 2122 patients during a median 
(IQR) follow-up of 2.6 (2.1–4.0) years. The pooled inci-
dence rate of all-cause mortality was 2.16 (95% CI, 
1.90–2.42) per 100 person-years (Figure II in the Data 
Supplement). The funnel plot and Egger regression 
asymmetry test suggest possible publication bias (Egger 
test, P=0.006). After addition of 6 hypothetical studies 
in the trim-and-ﬁll sensitivity analysis, the pooled inci-
dence rate decreased to 1.88 (95% CI, 1.60–2.16) per 
100 person-years.
There was a substantial statistical heterogeneity 
among studies (I2=78.1%; P<0.0001). In meta-regres-
sion analyses, the proportion of male sex and the per-
centage of individuals with NYHA >2 were positively 
associated with all-cause mortality. In subgroups strati-
ﬁed by LVEF, studies including patients with moderate-
to-severe LV impairment (LVEF <45%) appeared to have 
a higher incidence of all-cause deaths (P for subgroup 
difference, 0.011). The leave-one-out analysis was con-
sistent with the overall result.
Stroke and Systemic Emboli
The event rates of stroke and systemic emboli were 
reported in 15 studies accounting for 1332 patients 
with a median (IQR) follow-up of 2.7 (2.4–3.8) years. 
The pooled incidence rate was 1.54 (95% CI, 1.22–
1.86) per 100 person-years (Figure III in the Data Sup-
plement). We did not observe asymmetry in the funnel 
plot. Similar to the primary outcome, we identiﬁed a 
substantial heterogeneity among studies (I2=73.4%; 
Steffel47 2011 Retrospective 
single-center study 
of LVNC patients
None 74 43±16 53 Jenni 40±19 32.7±10 
mm/m2
57.9±41.5 All-cause mortality, 
CV mortality, 
ventricular 
arrhythmia
Stollberger48 2018 Prospective single-
center study of 
LVNC patients; 
prevalence of 
neuromuscular 
disease associated 
with LVNC was 
also assessed
None 273 53±17 193 Stöllberger NR 60±13 88.8±68.4 All-cause mortality, 
CV mortality, ICD 
implantation, 
cardiac 
transplantation
Tian49 2014 Retrospective 
single-center study 
of LVNC patients
None 106 46±17 83 Jenni 39±14 61±10 mm 35±25 All-cause mortality, 
CV mortality, 
thromboembolic 
event, ventricular 
arrhythmia, ICD 
implantation, 
cardiac 
transplantation, 
heart failure
Tian50 2017 Prospective single-
center study 
of older LVNC 
patients (age 
≥60 y)
None 35 65±5 28 Petersen 30±11 67±8 mm 35±28 All-cause mortality, 
CV mortality, heart 
failure, ventricular 
arrhythmia, ICD 
implantation
Waning51 2018 Retrospective 
multicenter study 
of LVNC patients
None 275 45 148 Jenni+
Petersen
NR NR 60 All-cause mortality, 
thromboembolic 
event, cardiac 
transplantation, 
ventricular 
arrhythmia, 
heart failure, ICD 
implantation
CV indicates cardiovascular; DCM, dilated cardiomyopathy; HCM, hypertrophic cardiomyopathy; ICD, implantable cardioverter deﬁbrillator; LVEDD, left ventricular end-
diastolic diameter; LVEF, left ventricular ejection fraction; LVNC, left ventricular noncompaction; MI, myocardial infarction; and NR, not reported.
*Unadjusted or indexed LVEDD or volume.
†The original study by Kawasaki et al also reported the event rates in 40 healthy volunteers, but these individuals were not included in the control group for this study.
Table. Continued
Author Year
Cohort 
Characteristics Control Group N Age, y
Male 
Sex, 
n
LVNC Imaging 
Diagnostic 
Criteria LVEF, %
LV End-
Diastolic 
Dimension*
Follow-Up 
Duration, 
mo End Points
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P<0.0001). Meta-regression analyses did not reveal 
any mediating inﬂuence of age, sex, NYHA classiﬁ-
cation, LV end-diastolic diameter or prevalent atrial 
ﬁbrillation. Stratiﬁcation by the study quality, LVEF, 
or person-time at risk did not show signiﬁcant dif-
ferences in the events rates between subgroups. The 
leave-one-out sensitivity analysis showed no evidence 
of bias introduced by any one study.
Heart Failure Hospitalization
Twelve studies (1028 patients; median [IQR] follow-up, 
2.5 [2.1–2.9] years) reported the incidence of heart 
failure hospitalization. The pooled event rate of heart 
failure hospitalization was 3.53 (95% CI, 2.95–4.11) 
per 100 person-years (Figure IV in the Data Supple-
ment). The funnel plot did not appear asymmetrical. 
There was a considerable between-study heterogene-
ity (I2=87.7%; P<0.0001). Meta-regression analyses 
identiﬁed a positive association between the propor-
tion of symptomatic heart failure (NYHA >2) at base-
line and the incidence of heart failure admission at 
follow-up (regression coefﬁcient, 0.04 per 1% increase 
in proportion of cohort with NYHA >2; P=0.049). In 
subgroup analyses, studies with an aggregate person-
time at risk >300 years appeared to have a lower 
incidence rate (2.77 [95% CI, 1.89–3.66], I2=92.5%, 
versus 3.97 [95% CI, 3.34–4.60] per 100 person-
years, I2=71.6%; P for subgroup difference, 0.031). 
The leave-one-out analysis was consistent with the 
overall pooled estimate.
Heart Transplantation
Data on cardiac transplantation rate were available in 
14 studies (1576 patients; median [IQR] follow-up, 2.8 
[2.4–4.9] years). The overall pooled event rate of heart 
transplantation was 1.24 (95% CI, 0.98–1.50) per 100 
person-years (Figure V in the Data Supplement). The 
funnel plot showed sparsely distributed studies with evi-
dence of asymmetry (Egger P<0.0001). After addition 
of 1 hypothetical study in the trim-and-ﬁll sensitivity 
analysis, the pooled incidence rate decreased minimal-
ly to 1.22 (95% CI, 0.96–1.48) per 100 person-years. 
The statistical heterogeneity of studies reporting heart 
transplantation outcome was substantial (I2=71.6%; 
P<0.0001). Meta-regression analyses did not reveal 
any mediating effect of the selected covariates. We 
again found a lower incidence of heart transplanta-
tion in the subgroup with an aggregate person-time at 
risk >300 years (1.04 [95% CI, 0.81–1.26], I2=60.3%, 
versus 1.79 [95% CI, 1.31–2.27] per 100 person-
years, I2=35.1%; P for subgroup difference, 0.005). No 
undue inﬂuence from any single study was detected in 
the leave-one-out analysis.
Ventricular Arrhythmias
Nineteen studies with a total sample size of 1445 (medi-
an [IQR] follow-up of 2.8 [2.4–3.8] years) documented 
the incidence of ventricular arrhythmias. The calculated 
pooled event rate was 2.17 (95% CI, 1.78–2.56) per 
100 person-years (Figure VI in the Data Supplement). 
There was no convincing evidence of publication bias 
in the funnel plot (Egger P=0.05). We identiﬁed a 
substantial heterogeneity among studies (I2=84.4%; 
P<0.0001). Meta-regression analyses did not ﬁnd any 
signiﬁcant association with covariates, but the sub-
group with moderate-severe LV impairment (LVEF 
<45%) appeared to have a higher incidence of ventric-
ular arrhythmias (2.30 [95% CI, 1.72–2.88], I2=88.4%, 
versus 1.60 [95% CI, 1.23–1.97] per 100 person-years, 
I2=0%; P for subgroup difference, 0.047). The leave-
one-out analysis did not show any signiﬁcant deviation 
from the overall pooled result.
Figure 3. Distribution of study quality ac-
cording to Quality in Prognosis Studies tool.
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Cardiac Device Implantation
The incidence of cardiac device implantation was 
recorded in 15 studies (1278 patients; median [IQR] 
follow-up of 2.9 [2.0–3.8] years). The pooled incidence 
rate was 2.66 (95% CI, 1.93–3.39) per 100 person-
years (Figure VII in the Data Supplement). The funnel 
plot appeared sparse but symmetrical. A considerable 
between-study heterogeneity was present (I2=95.3%; 
P<0.0001). The meta-regression analyses identiﬁed a 
negative association between the proportion of male 
sex and the incidence of cardiac device implantation 
(regression coefﬁcient, −0.06 per 1% increase in male 
sex proportion; P=0.04). Stratiﬁed analyses did not 
ﬁnd any signiﬁcant subgroup difference although the 
inconsistency index (I2) appeared much lower in some 
subgroups. We did not ﬁnd any indication of bias in the 
leave-one-out analysis.
Comparison With DCM
Two studies of 22 reported the incidence of cardiovas-
cular death in a comparable group of DCM patients. 
Overall, the LVNC patients did not have signiﬁcantly 
higher cardiovascular mortality than the DCM group 
(pooled odds ratio, 1.10 [95% CI, 0.18–6.67]; Fig-
ure  743,44). The pooled event rate of cardiovascular 
death in a previously published meta-analysis of DCM 
patients21 (19 studies enrolling 2466 individuals) was 
comparable to the pooled event rate observed in our 
study (DCM, 1.92 [95% CI, 1.44–2.39] cardiovascu-
lar deaths per 100 person-years versus LVNC, 1.92 
[95% CI, 1.54–2.30] cardiovascular deaths per 100 
person-years; Figure 6D). Two studies of 24 provided 
all-cause mortality data in a DCM control group. In 
comparison with the DCM group, patients with LVNC 
did not have signiﬁcantly higher mortality (pooled 
odds ratio, 0.67 [95% CI, 0.28–1.59]). When com-
pared with an external previously published DCM 
meta-analysis,21 the heart failure hospitalization rate 
in our study was signiﬁcantly higher (3.53 versus 
2.37 per 100 person-years; P=0.003). There was no 
signiﬁcant difference in the incidence rate of ventric-
ular arrhythmias between our study and the previous 
DCM meta-analysis21 (2.17 for LVNC versus 2.14 for 
DCM per 100 person-years; P=0.93).
DISCUSSION
In this meta-analysis investigating the prognosis of 
a large population of adult LVNC patients classiﬁed 
according to contemporary imaging criteria, we identi-
ﬁed the following key ﬁndings: (1) the overall incidence 
rates of cardiovascular mortality, all-cause mortality, 
stroke and systemic emboli, heart failure admission, 
cardiac transplantation, ventricular arrhythmias, and 
cardiac device implantation were 1.92, 2.16, 1.54, 
Figure 4. Forest plot demonstrating the individual and overall incidences of cardiovascular deaths per 100 person-years. 
The vertical dotted line indicates the pooled average incidence rate.?????????????????????????????????????????????????????????????
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3.53, 1.24, 2.17, and 2.66, respectively, per 100 per-
son-years, at an intermediate-term follow-up; (2) the 
incidence of cardiovascular or all-cause mortality in 
LVNC patients was similar to DCM controls; (3) the high 
level of statistical heterogeneity was partly explained by 
the variability in clinical characteristics (LVEF in particu-
lar) and study characteristics such as sample size/study 
duration; (4) the incidence rate of ventricular arrhyth-
mias was comparable to DCM patients, but heart fail-
ure admission rate was higher in LVNC patients.
By investigating the prognosis of real-world patients 
with excessive trabeculations meeting the imaging 
diagnostic criteria for LVNC, we aimed to provide much 
needed information on the natural course of this con-
troversial disease entity. The ﬁndings from our study 
can be regarded as a foundation for further discussion 
regarding the medical implications of an increasingly 
recognized imaging ﬁnding and also highlight impor-
tant heterogeneity among available published studies.
The incidence rates of cardiovascular and all-cause 
mortality, arguably, 2 more reliable and objective out-
comes, estimated to be 1.92 and 2.14 per 100 person-
years, respectively, in our meta-analysis, are 25- and 
5-fold higher than the event rates in a general popula-
tion (0.08 and 0.41 per 100 person-years for cardio-
vascular and all-cause mortality, respectively, in 45- to 
54-year age group in a North American population).52 
Therefore, a diagnosis of LVNC by current clinical and 
imaging criteria appears to portend a heightened 
mortality risk despite a signiﬁcant diversity of patient 
population in the individual studies. Nonetheless, when 
compared with nonischemic DCM patients, LVNC 
patients carry a similar risk of death from cardiovascular 
causes. We also observed elevated incidences of car-
diovascular morbidities in LVNC patients with 2 most 
frequent complications being heart failure hospitaliza-
tion and cardiac device implantation. The heart failure–
related hospital admission rate in our meta-analysis was 
higher than the pooled incidence observed in a com-
parable DCM meta-analysis (3.52 versus 2.37 per 100 
person-years). This ﬁnding should be interpreted with 
caution in view of variability in deﬁnition of heart failure 
decompensation and lack of data on the rigor of heart 
failure treatment.
There is a notion of an increased risk of systemic 
thromboembolism attributable to the sluggish blood 
ﬂow in the deep intertrabecular recesses in LVNC 
patients. However, no solid evidence is available to sup-
port this hypothesis. Indeed, in our study, the incidence 
rate of stroke and systemic emboli was 1.54 per 100 
person-years, which is either lower than or compara-
ble to the event rates reported in (1) V-HeFT trials in 
patients with systolic heart failure (2.1–2.7 per 100 per-
son-years), (2) patients with ischemic cardiomyopathy 
(1.5 per 100 person-years) in SAVE trial,53 and (3) DCM 
patients (3.5 per 100 person-years).54,55
It is important to consider the incidence rates report-
ed in this meta-analysis in the context of cohort char-
acteristics where 18 of 28 included studies recruited 
individuals with signiﬁcant LV systolic impairment. 
Subgroup analysis stratiﬁed by LVEF demonstrated a 
signiﬁcant reduction in the number of cardiovascular 
deaths in the absence of moderate-to-severe LV systolic 
dysfunction. Therefore, the risk of achieving the end 
Figure 5. Funnel plot for cardiovascular (CV) 
mortality. 
The red dots represent the original studies included 
in the meta-analysis while the blue dots represent the 
missing studies imputed by the trim-and-ﬁll method. 
The vertical dashed line indicates the original pooled 
incidence rates, and the vertical solid line indicates 
the revised pool incidence rates after inclusion of the 
imputed missing studies to counter publication bias.
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point may, in part, be contingent on the development 
of LV dysfunction. Although the risk to individuals with 
excessive trabeculations in an unselected and otherwise 
healthy population is beyond the scope of this study, a 
previous population study of ≈3000 asymptomatic indi-
viduals did not ﬁnd any association between the degree 
of trabeculation and the decline in LV function or inci-
dent cardiovascular events over a course of ≈10 years.56
As anticipated, we observed a high degree of sta-
tistical heterogeneity among included studies that can 
be partially explained by the differences in cohort char-
acteristics and study quality. In our quality assessment 
by Quality in Prognosis Studies criteria, the 2 most 
commonly affected bias domains were study participa-
tion (ie, selection bias) and treatment of confounders, 
reﬂecting the challenges associated with the observa-
tional studies reporting a relatively rare condition. The 
subsequent meta-regression and subgroup analyses 
revealed that severity of LV impairment measured by 
LVEF had an important inﬂuence on the variability of 
incidence rates reported in individual studies. Equiva-
lently, smaller studies with short follow-up duration 
tended to report higher incidence rates of secondary 
outcomes. The indicator of between-study variability (I2 
Figure 7. Forest plot of cardiovascular 
mortality in left ventricular noncompac-
tion (LVNC) patients compared with dilated 
cardiomyopathy (DCM) controls. 
The vertical dotted line represents the pooled 
odds ratio.
Figure 6. Subgroup analyses for cardiovascular mortality. 
A Incidence of cardiovascular mortality in subgroups stratiﬁed by person-years >300; (B) incidence of cardiovascular mortality in subgroups stratiﬁed by left 
ventricular ejection fraction (LVEF) <45%; (C) incidence of cardiovascular mortality in subgroups stratiﬁed by high vs low-moderate risk of bias; (D) incidence of 
cardiovascular mortality in left ventricular noncompaction (LVNC) meta-analysis vs external dilated cardiomyopathy (DCM) meta-analysis. The vertical dotted line 
indicates the pooled average incidence rate.
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index) was noticeably lower in the subgroup analysis, 
which further supports the importance of well-deﬁned 
inclusion and diagnostic criteria.
All imaging diagnostic criteria for LVNC consider the 
presence of excessive trabeculation as a cardinal sig-
nature of disease. There is a degree of confusion and 
uncertainty in assigning the disease status because of 
not-so-infrequent ﬁnding of increased trabeculation in 
otherwise healthy individuals and those with primary 
DCM or hypertrophic cardiomyopathy. Recent evidence 
suggests that the extent of trabeculation in asymptom-
atic low-risk population, LVNC, and DCM patients does 
not determine prognosis.24,25,56 In this respect, the lack 
of mediating inﬂuence by the LVNC/LV compaction ratio 
on clinical outcomes in our study is concordant with 
the existing evidence in literature. A recently published 
meta-analysis of 4 cardiovascular magnetic resonance 
studies enrolling LVNC patients reported that in the 
absence of late gadolinium enhancement and LV sys-
tolic dysfunction, no hard cardiac event was observed.57 
Therefore, our study, together with mounting evidence 
from existing literature, underscores the important 
prognostic role of focal myocardial injury and functional 
impairment, rather than the morphological appearance 
of LVNC. Indeed, it is notable that the conventional 
diagnostic criteria for LVNC have relied principally on 
ratio measurement and have not included other struc-
tural, functional, clinical, or familial parameters.
In this study, we systematically reviewed and per-
formed the meta-analysis of the incidence of impor-
tant cardiovascular outcomes in a large population of 
real-world LVNC patients. We attempted to synthesize 
the results in a robust manner giving due consideration 
to address potential biases where possible. However, 
we acknowledge several limitations associated with 
our study. First, the pooled analysis relied on observa-
tional, mostly single-center, cohort studies with vari-
able methodological quality as highlighted in the bias 
assessment, inclusion criteria, and deﬁnitions of LVNC. 
Second, our study only focused on the adult population 
mostly free from congenital heart disease; thus, the 
insights obtained from this work cannot be extended 
to pediatric LVNC or patients with coexisting congenital 
heart disease. Third, comparison of the rates of incident 
cardiovascular events between LVNC and hypertrophic 
cardiomyopathy was not performed and should be 
investigated in a future study. Fourth, meta-regression 
analyses were limited to the studies without missing 
covariate information, hence, may be underpowered. 
Fifth, only a few studies reported the incidence rates 
in a comparable DCM cohort. Thus, the precision of 
pooled odds ratio and the level of evidence are weaker. 
Finally, the incidence rates of adverse events observed 
in this study only hold true for an intermediate follow-
up duration, and the long-term consequences of LVNC 
remain to be elucidated.
An expert group consensus approach to harmo-
nize the diagnostic criteria, risk factors, and end 
points is urgently needed to develop a more stan-
dardized assessment of LVNC. Future studies includ-
ing prospective registries should address long-term 
prognosis and could also investigate additional prog-
nostic information provided by fractal analysis, T1 
mapping, and genotype over current LVNC/LV com-
paction ratio, systolic function, and tissue character-
ization by late gadolinium enhancement.
CONCLUSIONS
Patients with LVNC have similar risks of cardiovascular 
mortality, all-cause mortality, thromboembolic com-
plications, and ventricular arrhythmias in comparison 
with DCM patients. The ﬁnding of increased incidence 
of heart failure hospitalization in isolation should be 
interpreted with caution and investigated in future, 
well-designed studies. Traditional indicators of cardiac 
disease severity such as low LVEF, not the burden of 
trabeculation, appear to be associated with worse 
outcomes.
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